Skip to Main Content

A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata (AZURE)

Conditions

Diseases of the Integumentary System

Phase II

What is the purpose of this trial?

Efficacy and safety of rosnilimab (ANB030) in subjects with moderate-to-severe Alopecia Areata

  • Trial with
    AnaptysBio Inc.
  • Start Date
    05/10/2022
  • End Date
    01/19/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    05/18/2022
  • Study HIC
    #2000032418